CYTK Earnings

CYTK reported its earnings on 2026-05-05, showcasing a revenue of 19.36M against an estimate of 7.08M, resulting in a 173.38% surprise. The EPS was -1.67, surpassing the expected -1.67 by 0%. The stock experienced a -2.92% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following CYTK's earnings announcement on 2026-05-05, the stock price moved by -2.92% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, CYTK's stock price tends to shift by an average of -2.24% in the 10 days leading up to earnings and -3.55% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate CYTK's annual revenue to reach 19.87M, while the EPS is projected at -1.58. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CYTK's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CYTK's stock price typically moves by -2.24% in the 10 days before its earnings and -3.55% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -1.58 and revenue of 19.87M.

The earnings call presents a balanced outlook. The commercial launch of MYQORZO and revenue growth are positive, but the ongoing net loss and increased R&D expenses are concerns. The Q&A section didn't highlight any additional risks or uncertainties. The lack of discussion on strategic initiatives, risks, and returns leaves gaps in the analysis. With no major new partnerships or guidance changes, the overall sentiment remains neutral, suggesting a limited impact on the stock price over the next two weeks.